Article content
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug tha
The Latest: Mexico president OKs states acquiring vaccines michigansthumb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from michigansthumb.com Daily Mail and Mail on Sunday newspapers.
The United States is closely watching the more infectious variant of COVID-19 after British officials warned that it may also be more deadly, two top U.S. health officials said on Saturday, cautioning more data is needed. Officials are somewhat more worried about a separate variant from South Africa, although it has not yet been identified among U.S. cases of the novel coronavirus, National Institutes of Health (NIH) Director Francis Collins and Dr. Anthony Fauci, President Joe Biden's top COVID-19 medical adviser, also said.
The Latest: Immigrant wariness a hurdle for vaccine efforts kvia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kvia.com Daily Mail and Mail on Sunday newspapers.